Therefore, the targeting of TRIP4 in conjunction with hTERT and the PI3K/AKT pathway can serve as potential therapeutic strategies for overcoming radiotherapy resistance in cervical cancer. This evidence concerns the gene AKT1 and cervical carcinoma.